Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer.
Identifieur interne : 000436 ( Main/Exploration ); précédent : 000435; suivant : 000437Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer.
Auteurs : Robert Haddad [États-Unis]Source :
- Expert opinion on therapeutic targets [ 1744-7631 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Antinéoplasiques (administration et posologie), Carcinome épidermoïde (métabolisme), Carcinome épidermoïde (traitement médicamenteux), Communication interdisciplinaire (MeSH), Humains (MeSH), Systèmes de délivrance de médicaments (méthodes), Systèmes de délivrance de médicaments (tendances), Tumeurs de la tête et du cou (métabolisme), Tumeurs de la tête et du cou (traitement médicamenteux).
- MESH :
- administration et posologie : Antinéoplasiques.
- métabolisme : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- méthodes : Systèmes de délivrance de médicaments.
- tendances : Systèmes de délivrance de médicaments.
- traitement médicamenteux : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- Animaux, Communication interdisciplinaire, Humains.
English descriptors
- KwdEn :
- Animals (MeSH), Antineoplastic Agents (administration & dosage), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (metabolism), Drug Delivery Systems (methods), Drug Delivery Systems (trends), Head and Neck Neoplasms (drug therapy), Head and Neck Neoplasms (metabolism), Humans (MeSH), Interdisciplinary Communication (MeSH).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents.
- drug therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- metabolism : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- methods : Drug Delivery Systems.
- trends : Drug Delivery Systems.
- Animals, Humans, Interdisciplinary Communication.
Abstract
The treatment of head and neck cancer continues to represent a major challenge. Patients are typically treated with chemotherapy, radiation and surgery. Multiple resources are needed to allow patients to go through the treatment, and recovery can take months and often years. Those resources include, nutritionists, speech and swallow therapists, social workers, psychiatrists and dentists. It is of paramount importance that these patients have access to a multi-disciplinary clinic that can best manage the problems that will invariably arise when treatment is started. These include mucositis, pain, xerostomia, swallowing dysfunction, depression, loss of work and severe deconditioning. Recent advances in the treatment of head and neck cancer have resulted in an improvement in survival. These advances have included the use of newer chemotherapeutic agents, better radiation planning and delivery and better surgical techniques. This report highlights some of the data presented in the first multidisciplinary symposium on head and neck cancer. Special attention is given to the use of newer 'targeted agents' and their incorporation in the definitive therapy with chemotherapy and radiation. Major focus is placed on epidermal growth factor inhibitors and their potential role both in the curative and recurrent settings.
DOI: 10.1517/14728222.10.2.333
PubMed: 16548781
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer.</title><author><name sortKey="Haddad, Robert" sort="Haddad, Robert" uniqKey="Haddad R" first="Robert" last="Haddad">Robert Haddad</name><affiliation wicri:level="2"><nlm:affiliation>Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Robert_haddad@dfci.harvard.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16548781</idno><idno type="pmid">16548781</idno><idno type="doi">10.1517/14728222.10.2.333</idno><idno type="wicri:Area/Main/Corpus">000440</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000440</idno><idno type="wicri:Area/Main/Curation">000440</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000440</idno><idno type="wicri:Area/Main/Exploration">000440</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer.</title><author><name sortKey="Haddad, Robert" sort="Haddad, Robert" uniqKey="Haddad R" first="Robert" last="Haddad">Robert Haddad</name><affiliation wicri:level="2"><nlm:affiliation>Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Robert_haddad@dfci.harvard.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic targets</title><idno type="eISSN">1744-7631</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antineoplastic Agents (administration & dosage)</term><term>Carcinoma, Squamous Cell (drug therapy)</term><term>Carcinoma, Squamous Cell (metabolism)</term><term>Drug Delivery Systems (methods)</term><term>Drug Delivery Systems (trends)</term><term>Head and Neck Neoplasms (drug therapy)</term><term>Head and Neck Neoplasms (metabolism)</term><term>Humans (MeSH)</term><term>Interdisciplinary Communication (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antinéoplasiques (administration et posologie)</term><term>Carcinome épidermoïde (métabolisme)</term><term>Carcinome épidermoïde (traitement médicamenteux)</term><term>Communication interdisciplinaire (MeSH)</term><term>Humains (MeSH)</term><term>Systèmes de délivrance de médicaments (méthodes)</term><term>Systèmes de délivrance de médicaments (tendances)</term><term>Tumeurs de la tête et du cou (métabolisme)</term><term>Tumeurs de la tête et du cou (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Systèmes de délivrance de médicaments</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Systèmes de délivrance de médicaments</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Delivery Systems</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Interdisciplinary Communication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Communication interdisciplinaire</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The treatment of head and neck cancer continues to represent a major challenge. Patients are typically treated with chemotherapy, radiation and surgery. Multiple resources are needed to allow patients to go through the treatment, and recovery can take months and often years. Those resources include, nutritionists, speech and swallow therapists, social workers, psychiatrists and dentists. It is of paramount importance that these patients have access to a multi-disciplinary clinic that can best manage the problems that will invariably arise when treatment is started. These include mucositis, pain, xerostomia, swallowing dysfunction, depression, loss of work and severe deconditioning. Recent advances in the treatment of head and neck cancer have resulted in an improvement in survival. These advances have included the use of newer chemotherapeutic agents, better radiation planning and delivery and better surgical techniques. This report highlights some of the data presented in the first multidisciplinary symposium on head and neck cancer. Special attention is given to the use of newer 'targeted agents' and their incorporation in the definitive therapy with chemotherapy and radiation. Major focus is placed on epidermal growth factor inhibitors and their potential role both in the curative and recurrent settings.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16548781</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7631</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert opinion on therapeutic targets</Title><ISOAbbreviation>Expert Opin Ther Targets</ISOAbbreviation></Journal><ArticleTitle>Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer.</ArticleTitle><Pagination><MedlinePgn>333-6</MedlinePgn></Pagination><Abstract><AbstractText>The treatment of head and neck cancer continues to represent a major challenge. Patients are typically treated with chemotherapy, radiation and surgery. Multiple resources are needed to allow patients to go through the treatment, and recovery can take months and often years. Those resources include, nutritionists, speech and swallow therapists, social workers, psychiatrists and dentists. It is of paramount importance that these patients have access to a multi-disciplinary clinic that can best manage the problems that will invariably arise when treatment is started. These include mucositis, pain, xerostomia, swallowing dysfunction, depression, loss of work and severe deconditioning. Recent advances in the treatment of head and neck cancer have resulted in an improvement in survival. These advances have included the use of newer chemotherapeutic agents, better radiation planning and delivery and better surgical techniques. This report highlights some of the data presented in the first multidisciplinary symposium on head and neck cancer. Special attention is given to the use of newer 'targeted agents' and their incorporation in the definitive therapy with chemotherapy and radiation. Major focus is placed on epidermal growth factor inhibitors and their potential role both in the curative and recurrent settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Robert_haddad@dfci.harvard.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Ther Targets</MedlineTA><NlmUniqueID>101127833</NlmUniqueID><ISSNLinking>1472-8222</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033183" MajorTopicYN="Y">Interdisciplinary Communication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16548781</ArticleId><ArticleId IdType="doi">10.1517/14728222.10.2.333</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Haddad, Robert" sort="Haddad, Robert" uniqKey="Haddad R" first="Robert" last="Haddad">Robert Haddad</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000436 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000436 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16548781
|texte= Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16548781" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |